Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790582 · ClinicalTrials.gov registry record · Phase 2
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Forbes Norris MDA/ALS Research Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
- 10
- Study locations
NCT00790582 is a Phase 2 study of Amyotrophic Lateral Sclerosis that has completed, run by Forbes Norris MDA/ALS Research Center. The registered enrollment target is 109 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (88% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT00790582, a Phase 2 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Forbes Norris MDA/ALS Research Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease. Since there is no placebo in this study, all patients will be taking lithium carbonate.
Conditions Studied
Interventions
- DRUG lithium carbonate
Study Locations (10)
California
- UCLA Neuromuscular Research Center - Los Angeles
- UC Irvine MDA/ALS & Neuromuscular Center - Orange
- California Pacific Medical Center - San Francisco
Arizona
- Mayo Clinic - Scottsdale
Kansas
- Kansas University Medical Center - Kansas City
Missouri
- Washington University Department of Neurology - St Louis
Oregon
- Providence ALS Clinic - Portland
Pennsylvania
- University of Pennsylvania Neurological Institute - Philadelphia
Texas
- Methodist Neurological Institute - Houston
Utah
- University of Utah Clinical Neurosciences Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790582
The ClinicalTrials.gov registry entry for NCT00790582 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (88% lower). The listed sponsor is Forbes Norris MDA/ALS Research Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which lithium carbonate is the first listed.
NCT00790582 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Kansas.
Frequently Asked Questions
What is clinical trial NCT00790582 about?
NCT00790582 is a clinical study titled "A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)". This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease. Since there is no placebo in this study, all patients will be taking lithium carbonat...
What is the current status of trial NCT00790582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2008-05. Estimated completion is 2010-03.
What conditions does trial NCT00790582 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT00790582?
The interventions under investigation include: lithium carbonate (DRUG).
Who is sponsoring clinical trial NCT00790582?
This trial is sponsored by Forbes Norris MDA/ALS Research Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00790582 being conducted?
This trial has 10 study locations across Arizona, California, Kansas, Missouri, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.